In 88 RET-mutant MTC patients who had not previously received vandetanib or cabozantinib, the response rate was 73% (95% CI: 62–82), and the 1-year PFS 92% (95% CI: 82–97). Here, RET is linked to medullary thyroid gland carcinoma.